Summary table assessment of the use of 21 selected generic drug products including, Rosiglitazone/metformin hydrochloride (HCL), Rosiglitazone/Glimperide, Varenicline Tartrate, Propoxyphene HCL, Alvimopan, Isotretinoin, Ambrisentan, Alosetron HCL, Sibutramine Hydrochloride, Metoclopramide HCL, Lenalidomide, Buprenorphine HCL/Noloxone HCL, Buprenorphine HCL, Nilotinib Hydrochloride, Thalidomide, Bosentan, Burpopion HCL, Ribavirin/interferon A-2B, Sacrosidase, Propoxyphene HCL/Acetaminophen, and Propoxyphene HCL/ASA/Caffeine. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in September-October 2012. This report includes data from 16 Data Partners.
If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to firstname.lastname@example.org.
The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.